OncoMatch

OncoMatch/Clinical Trials/NCT03681561

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Is NCT03681561 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Ruxolitinib and Nivolumab for hodgkin lymphoma.

Phase 1/2RecruitingVeronika BachanovaNCT03681561Data as of May 2026

Treatment: Ruxolitinib · Nivolumab — This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: checkpoint inhibitor (nivolumab, pembrolizumab)

Prior therapy with check-point inhibitors (nivolumab, pembrolizumab, others) and subsequent progressive disease, stable disease, mixed response, or relapse

Lab requirements

Blood counts

Absolute Neutrophil Count ≥ 1000/μL; Platelets ≥ 75,000/μL (or ≥50,000/mm3 if known BM involvement)

Kidney function

Calculated creatinine clearance ≥ 40 cc/min using the Cockcroft-Gault formula

Liver function

Bilirubin ≤ 1.5 x upper limit of normal (ULN); AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN

Absolute Neutrophil Count ≥ 1000/μL; Platelets ≥ 75,000/μL (or ≥50,000/mm3 if known BM involvement); Calculated creatinine clearance ≥ 40 cc/min using the Cockcroft-Gault formula; Bilirubin ≤ 1.5 x upper limit of normal (ULN); AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Illinois Cancer Center · Chicago, Illinois
  • Indiana Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
  • University of Iowa Hospitals and Clinics · Iowa City, Iowa
  • University of Minnesota · Minneapolis, Minnesota
  • Ohio State University Comprehensive Cancer Center · Columbus, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify